Edwards and Cook Combine on Possible Living Heart Valve

Edwards Lifesciences entered into a biomaterials deal with Cook Biotech in an effort to develop a living heart valve using biomaterials.

Medical device companies, led by Edwards Lifesciences Corp. , have made considerable progress in developing tissue-based replacement heart valves that in many cases can be used instead of traditional mechanical valves, eliminating the need for patients to remain on a lifelong anticoagulation drug regimen. (See "Edwards: Will a Biotech Deal Strategy Work for a Device Company?" IN VIVO, September 2002Also see "Edwards: Will a Biotech Deal Strategy Work For a Device Company?" - In Vivo, 1 September, 2002. and "Edwards' Winning Heart Valve Strategy," IN VIVO, April 2002 Also see "Edwards' Winning Heart Valve Strategy" - In Vivo, 1 April, 2002..) The longstanding advantage of mechanical valves is that they typically out-last the patients in which they are implanted because they basically don't wear out. The challenge for product companies has been coming up with tissue valves of sufficient longevity to make them viable options, particularly as patients are living longer and valves are being implanted in younger patients.

"There's a big unmet clinical need, particularly for younger patients, to have heart valves that can last a lifetime and...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on In Vivo for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Innovation

This Belgian Biotech’s Drug Cocktail Could Help Reverse Muscle Aging

 
• By 

While big pharma pours billions into creating new anti-aging molecules, a Belgian startup has taken a different path: combining existing safe drugs with AI precision. The early results suggest it might be onto something revolutionary.

Podcast: Brain+ CEO Discusses “Groundbreaking” Potential Of CST Assistant For Dementia Patients

 

Devika Wood, CEO of Brain+, explains the importance of developing health tech solutions for dementia and the growing need to both raise awareness and improve overall access to nondrug interventions like CST.

The Goldilocks Isotope: Perspective Therapeutics’ ‘Just Right’ Alpha Radiotherapeutic

 
• By 

Thijs Spoor's bet on lead-212 is paying off as Perspective Therapeutics advances three clinical programs with promising early efficacy signals and a comprehensive manufacturing strategy.

Johnson & Johnson MedTech: How To Scale Digital Solutions

 

J&J's EMEA head of digital solutions, Julia Fishman, talks about the hurdles in scaling digital innovation and what’s up next on J&J’s innovation road map. Robot-assisted surgery pioneer Ivo Broeders gives his perspective on the difficulties in clinical adoption.

More from In Vivo

Podcast: Brain+ CEO Discusses “Groundbreaking” Potential Of CST Assistant For Dementia Patients

 

Devika Wood, CEO of Brain+, explains the importance of developing health tech solutions for dementia and the growing need to both raise awareness and improve overall access to nondrug interventions like CST.

Behind The Buyout: Dispatches From The Dealmaking Table

 
• By 

In a challenging funding environment for biopharma, strategic dealmaking has become a critical growth engine. In Vivo explores what it truly takes to navigate high-stakes acquisitions and partnerships, drawing on insights from seasoned industry leaders.

Crisis Or Opportunity? US MFN Policy Could Test Japan’s Appetite For Reforms

 
• By 

While the adoption of most favored nation drug pricing in the US stands to affect Japanese biopharma firms now heavily reliant on this market, it might also present an opportunity for pricing and policy reforms at home.